Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-27T07:54:43.416Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science: (March 2009)

Published online by Cambridge University Press:  01 August 2009

R. Sutherland
R. Sutherland
Affiliation:
Cancer Research ProgramGarvan Institute of Medical ResearchDarlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Information
Breast Cancer Online , Volume 12 , Issue 8 , August 2009 , e15
Copyright
Copyright © Cambridge University Press 2009

References

1.Aaltonen, K, Amini, RM, Heikkila, P, Aittomaki, K, Tamminen, A, Nevanlinna, H, Blomqvist, C. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009; 100: 1055–1060.CrossRefGoogle ScholarPubMed
2.Al-Bazz, YO, Underwood, JCE, Brown, BL, Dobson, PRM. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 2009; 45: 694–704.CrossRefGoogle ScholarPubMed
3.Aurisicchio, L, Peruzzi, D, Conforti, A, Dharmapuri, S, Biondo, A, Giampaoli, S, Fridman, A, Bagchi, A, Winkelmann, CT, Gibson, R, Kandimalla, ER, Agrawal, S, Ciliberto, G, La Monica, N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9. Clin Cancer Res 2009; 15: 1575–1584.CrossRefGoogle Scholar
4.Bertucci, F, Finetti, P, Cervera, N, Charafe-Jauffret, E, Buttarelli, M, Jacquemier, J, Chaffanet, M, Maraninchi, D, Viens, P, Birnbaum, D. How different are luminal A and basal breast cancers? Int J Cancer 2009; 124: 1338–1348.CrossRefGoogle ScholarPubMed
5.Blevins-Primeau, AS, Sun, D, Chen, G, Sharma, AK, Gallagher, CJ, Amin, S, Lazarus, P. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69: 1892–1900.CrossRefGoogle Scholar
6.Chisarnore, MJ, Wilkinson, HA, Flores, O, Chen, JD. Estrogen-related receptor-α antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Mol Cancer Ther 2009; 8: 672–681.CrossRefGoogle Scholar
7.Creighton, CJ, Osborne, CK, van de Vijver, MJ, Foekens, JA, Klijn, JG, Horlings, HM, Nuyten, D, Wang, Y, Zhang, Y, Chamness, GC, Hilsenbeck, SG, Lee, AV, Schiff, R. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287–299.CrossRefGoogle ScholarPubMed
8.Eubank, TD, Roberts, RD, Khan, M, Curry, JM, Nuovo, GJ, Kuppusamyl, P, Marsh, CB. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 2009; 69: 2133–2140.CrossRefGoogle ScholarPubMed
9.Finkbeiner, MR, Astanehe, A, To, K, Fotovati, A, Davies, AH, Zhao, Y, Jiang, H, Stratford, AL, Shadeo, A, Boccaccio, C, Comoglio, P, Mertens, PR, Eirew, P, Raouf, A, Eaves, CJ, Dunn, SE. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421–1431.CrossRefGoogle ScholarPubMed
10.Frogne, T, Benjaminsen, RV, Sonne-Hansen, K, Sorensen, BS, Nexo, E, Laenkholm, AV, Rasmussen, LM, Riese, DJ, de Cremoux, P, Stenvang, J, Lykkesfeldt, AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114: 263–275.CrossRefGoogle ScholarPubMed
11.Gobert, M, Treilleux, I, Bendriss-Vermare, N, Bachelot, T, Goddard-Leon, S, Arfi, V, Biota, C, Doffin, AC, Durand, I, Olive, D, Perez, S, Pasqual, N, Faure, C, Coquard, IR, Puisieux, A, Caux, C, Blay, JY, Menetrier-Caux, C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69: 2000–2009.CrossRefGoogle Scholar
12.Gonzalez, L, Zambrano, A, Lazaro-Trueba, I, Lopez, E, Gonzalez, JJA, Martin-Perez, J, Aranda, A. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 2009; 28: 1298–1308.CrossRefGoogle ScholarPubMed
13.Hirschfeld, M, zur Hausen, A, Bettendorf, H, Jager, M, Stickeler, E. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 2009; 69: 2082–2090.CrossRefGoogle ScholarPubMed
14.Hollmen, M, Maatta, JA, Bald, L, Sliwkowski, MX, Elenius, K. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009; 28: 1309–1319.CrossRefGoogle ScholarPubMed
15.Horlock, C, Stott, B, Dyson, PJ, Morishita, M, Coombes, RC, Savage, P, Stebbing, J. The effects of trastuzumab on the CD4+CD25+FoxP3+and CD4+IL17A+T-cell axis in patients with breast cancer. Br J Cancer 2009; 100: 1061–1067.CrossRefGoogle ScholarPubMed
16.Iorio, MV, Casalini, P, Piovan, C, Di Leva, G, Merlo, A, Triulzi, T, Menard, S, Croce, CM, Tagliabue, E. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195–2200.CrossRefGoogle ScholarPubMed
17.Loddo, M, Kingsbury, SR, Rashid, M, Proctor, I, Holt, C, Young, J, El-Sheikh, S, Falzon, M, Eward, KL, Prevost, T, Sainsbury, R, Stoeber, K, Williams, GH. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 2009; 100: 959–970.CrossRefGoogle ScholarPubMed
18.McCabe, N, Cerone, MA, Ohishi, T, Seimiya, H, Lord, CJ, Ashworth, A. Targeting tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009; 28: 1465–1470.CrossRefGoogle ScholarPubMed
19.Narayan, M, Wilken, JA, Harris, LN, Baron, AT, Kimbler, KD, Maihle, NJ. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 2009; 69: 2191–2194.CrossRefGoogle ScholarPubMed
20.Park, SA, Na, HK, Kim, EH, Cha, YN, Surh, YJ. 4-Hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of I κ B kinase: potential role of reactive oxygen species. Cancer Res 2009; 69: 2416–2424.CrossRefGoogle ScholarPubMed
21.Proietti, CJ, Rosemblit, C, Beguelin, W, Rivas, MA, Flaque, MCD, Charreau, EH, Schillaci, R, Elizalde, PV. Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol 2009; 29: 1249–1265.CrossRefGoogle ScholarPubMed
22.Reddy, BY, Greco, SJ, Patel, PS, Trzaska, KA, Rameshwar, P. RE-1-silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci U S A 2009; 106: 4408–4413.CrossRefGoogle ScholarPubMed
23.Redmond, AM, Bane, FT, Stafford, T, McLlroy, M, Dillon, MF, Crotty, TB, Hill, AD, Young, LS. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009; 15: 2098–2106.CrossRefGoogle ScholarPubMed
24.Sorensen, RB, Andersen, RS, Svane, IM, Engell-Noerregaard, L, Hadrup, SR, Balslev, E, Andersen, MH, Straten, PT. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res 2009; 15: 1543–1549.CrossRefGoogle ScholarPubMed
25.Umemura, S, Shirane, M, Takekoshi, S, Kusakabe, T, Itoh, J, Egashira, N, Tokuda, Y, Mori, K, Osamura, YR. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer 2009; 100: 764–771.CrossRefGoogle Scholar
26.van Agthoven, T, Veldscholte, J, Smid, M, van Agthoven, TLA, Vreede, L, Broertjes, M, de Vries, I, de Jong, D, Sarwari, R, Dorssers, LCJ. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009; 114: 23–30.CrossRefGoogle ScholarPubMed
27.Wu, XL, Hawse, JR, Subramaniam, M, Goetz, MP, Ingle, JN, Spelsberg, TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells. Cancer Res 2009; 69: 1722–1727.CrossRefGoogle ScholarPubMed
28.Xian, W, Pappas, L, Pandya, D, Selfors, LM, Derksen, PW, de Bruin, M, Gray, NS, Jonkers, J, Rosen, JM, Brugge, JS. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res 2009; 69: 2244–2251.CrossRefGoogle ScholarPubMed
29.Yamnik, RL, Digilova, A, Davis, DC, Brodt, ZN, Murphy, CJ, Holz, MK. S6 Kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. J Biol Chem 2009; 284: 6361–6369.CrossRefGoogle ScholarPubMed
30.Zheng, W, Long, JR, Gao, YT, Li, C, Zheng, Y, Xiang, YB, Wen, WQ, Levy, S, Deming, SL, Haines, JL, Gu, K, Fair, AM, Cai, QY, Lu, W, Shu, XO. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009; 41: 324–328.CrossRefGoogle ScholarPubMed
31.Zhou, Q, Geahlen, RL. The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells. Oncogene 2009; 28: 1348–1356.CrossRefGoogle ScholarPubMed